Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023

BUY
$3.86 - $5.0 $376,805 - $488,090
97,618 New
97,618 $420 Million
Q4 2022

Feb 14, 2023

BUY
$3.78 - $5.81 $368,996 - $567,160
97,618 New
97,618 $414,000
Q2 2022

Aug 15, 2022

SELL
$2.55 - $4.1 $2,029 - $3,263
-796 Reduced 0.81%
97,856 $299,000
Q3 2021

Nov 12, 2021

BUY
$3.57 - $5.6 $197,599 - $309,960
55,350 Added 127.82%
98,652 $471,000
Q2 2021

Aug 11, 2021

SELL
$3.46 - $4.92 $26,434 - $37,588
-7,640 Reduced 15.0%
43,302 $168,000
Q1 2021

May 13, 2021

SELL
$3.27 - $7.14 $3,358 - $7,332
-1,027 Reduced 1.98%
50,942 $238,000
Q4 2020

Feb 09, 2021

BUY
$1.94 - $3.19 $24,420 - $40,155
12,588 Added 31.96%
51,969 $159,000
Q1 2020

May 06, 2020

SELL
$1.35 - $4.06 $2,134 - $6,418
-1,581 Reduced 3.86%
39,381 $62,000
Q4 2019

Feb 14, 2020

BUY
$2.78 - $4.03 $3,347 - $4,852
1,204 Added 3.03%
40,962 $134,000
Q2 2019

Aug 12, 2019

SELL
$3.47 - $4.75 $170 - $232
-49 Reduced 0.12%
39,758 $144,000
Q1 2019

May 14, 2019

SELL
$3.85 - $5.53 $12,212 - $17,541
-3,172 Reduced 7.38%
39,807 $180,000
Q4 2018

Feb 11, 2019

BUY
$3.37 - $6.59 $144,839 - $283,231
42,979 New
42,979 $169,000

Others Institutions Holding ANIX

About Anixa Biosciences Inc


  • Ticker ANIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,661,700
  • Market Cap $96.6M
  • Description
  • Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...
More about ANIX
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.